Theravance Biopharma (TBPH) Net Cash Flow (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Net Cash Flow data on file, last reported at $120.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $120.3 million, up 65.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $177.5 million (up 212.59% YoY), and the FY2025 annual result was $130.0 million, up 7537.59% from the prior year.
• Net Cash Flow grew to $120.3 million in Q1 2026 per TBPH's latest filing, from -$7.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $974.8 million in Q4 2022 and troughed at -$744.1 million in Q3 2022.
• A 5-year average of $12.8 million and a median of -$7.0 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow jumped 3198.34% in 2022, then sank 2607.53% in 2023.
• A 5-year view of Net Cash Flow shows it stood at $974.8 million in 2022, then tumbled by 103.3% to -$32.1 million in 2023, then soared by 144.86% to $14.4 million in 2024, then slumped by 148.32% to -$7.0 million in 2025, then jumped by 1826.64% to $120.3 million in 2026.
• Business Quant data shows TBPH's Net Cash Flow at $120.3 million in Q1 2026, -$7.0 million in Q4 2025, and -$107.2 million in Q3 2025.